As CD40-mediated NFκB activation seems to be required for specific LAPTM5-mediated effects, these molecular mechanisms also explain the absence of LAPTM5-dependent effects in CD40-negative glioblastoma cells as summarized in Figure 6. The gene discussed is NFKB1; the disease is glioblastoma.